• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Alcami

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Syngene

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    09 Takeda

    ...

    09 Takeda
    Takeda became a Top 10 company this year after its $62 billion Shire purchase.
    Tim Wright, Editor, Contract Pharma07.15.20
    Headquarters: Osaka, Japan
    twitter.com/TakedaPharmaDe
    www.takeda.com


    Headcount: 49,578
    Year Established: 1781
    Revenues:  $30,519  (+2%)
    Net Income:  $410  (n/a)
    R&D:  $4,566  (+56%)

    TOP SELLING DRUGS  
    Drug Indication 2019 Sales  (+/-%)
    Entyvio ulcerative colitis, Crohn’s disease $3,194 32%
    Vyvanse  attention deficit disorder/hyperactivity $2,518 465%
    Gammafard Liquid immunoglobulin deficiency $2,151 312%
    Advate haemophilia A $1,453  402%
    Velcade multiple myeloma  $1,001 5%
    Leuplin prostate cancer  $798 1%
    Ninlaro  multiple myeloma $714 27%
    Azliva  hypertension $706  11%
    Takecab acid-related diseases  $669 27%
    Trintellix  depression $650  25%

    Takeda was catapulted into this year’s Top 10 after its massive $62 billion acquisition of Shire in 2018. The deal was finalized in January 2019 and is one of the largest international acquisition deals in Japan’s history. The mega deal doubled Takeda’s pharma revenues, which grew to $30.5 billion in 2019 from $16 billion the year before. Backed by the Shire deal, Takeda now has firm footing as a top 10 R&D driven global biopharmaceutical company.

    Broken down geographically, the U.S. led Takeda’s revenues, representing 48% of 2019 sales, followed by Europe and Canada (20%), Japan (18%) and growth and emerging markets (14%).
    Takeda’s transformed global business platform is focused on 5 key business areas—Gastroenterology (21% of 2019 sales), Rare Diseases (20%), Plasma Derived Therapies (12%), Oncology (13%), and Neuroscience (13%), with growing brands and a strong R&D pipeline of promising therapies in these areas.

    Takeda reported that its leading gastrointestinal (GI) therapy, Entyvio, its treatment for rare hereditary angioedema, Takhzyro, and plasma-derived therapies all delivered strong growth in 2019. Entyvio enjoyed a 33% sales spike while Takhzyro sales shot up 318%. Other notable contributors to 2019 revenue growth include the oncology drug Ninlaro, which grew 29%, neuroscience treatment Trintellix, up 25%, and the immunology drug Albumin/Flexbumin was up 20%.

    During the year, Takeda divested its eye drug Xiidra to Novartis for $5.3 billion and its TachoSil Fibrin Sealant Patch to Ethicon for $400 million as part of its strategy to focus on core business areas following the Shire deal.

    Takeda’s R&D engine is fueled by 14 global brands with more than 20 ongoing pivotal studies in new indications and geographies. The main drivers for new product launches are 12 unique New Molecular Entities (NMEs) in Wave 1, which Takeda says represent several potential best-in-class / first-in-class therapies targeted for launch by 2024 and have potential peak sales of more than $10 billion. In addition, Takeda has approximately 30 clinical-stage early development NMEs and next generation platforms under development.

    Takeda has major expansion plans in China with more than 15 planned approvals over the next five years. In fact, during the fourth quarter Takeda received approval for Entyvio in China for the treatment of patients with moderate to severe active ulcerative colitis and Crohn's disease.

    Bolstering its R&D capabilities in 2019, Takeda opened a new research facility in San Diego, CA. The 165,000-square-foot facility is home to more than 250 employees focused on leveraging specialized drug discovery technologies and advancing discovery research in gastroenterology and neuroscience.

    The facility is home to four research platform groups—structural biology, early target discovery, computational biology and biologics—that provide key capabilities to discover and advance promising molecules. The new research center in San Diego complements Takeda’s global Research & Development center in Cambridge, MA and its other global research site in Shonan, Japan.

    Takeda’s R&D efforts are in four therapeutic areas—oncology, gastroenterology (GI), neuroscience and rare diseases—with targeted investments also committed to plasma-derived therapies (PDT) and vaccines. More than 50 percent of Takeda’s research pipeline focuses on non-small molecules, including biologics, peptides, oligonucleotides, cell and gene therapy, the microbiome and other modalities.

    Immuno-oncology takes center stage
    At the beginning of 2019, Takeda formed new research collaborations in immuno-oncology, an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation cancer immunotherapies, including novel cell therapy approaches that may provide important opportunities for addressing the needs of patients with hard-to-treat cancers.

    Takeda is collaborating with Memorial Sloan Kettering Cancer Center to discover and develop novel chimeric antigen receptor T-cell (CAR-T) products for the treatment of multiple myeloma, acute myeloid leukemia and additional solid tumor indications.

    It exercised an option under its existing research collaboration with Noile-Immune Biotech, which originated in September 2017. Due to the success of the collaboration, Takeda exclusively licensed NIB-102 and NIB-103 for the treatment of various solid tumor indications, and will co-develop these CAR-T cell therapies with Noile utilizing the company’s proprietary “Prime” (proliferation inducing and migration enhancing) CAR-T platform.

    Takeda’s exercised option for an exclusive oncology-targeted Humabody license from Crescendo Biologics will allow it to additionally evaluate these Humabody VHs for the development of novel CAR-T therapeutics. The development will leverage the unique properties of single-domain tumor-targeted binders as an alternative to conventional single-chain variable fragment (scFv)-based approaches.

    Takeda’s diversification into next-generation cell therapy builds directly on its three strategic pillars in oncology: hematologic malignancies, lung cancer and immuno-oncology. Through collaboration with external partners and its newly established translational cell therapy engine, Takeda plans to deliver a rich pipeline of early-stage assets in the coming years.

    R&D partnerships
    During the year Takeda entered 38 new R&D collaborations with biotech and academia. With Evotec SE it entered a strategic, multi-year drug discovery collaboration to establish at least five drug discovery programs with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development.

    Sosei Group Corporation and Takeda entered into a multi-target partnership to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (GPCR) targets. The partnerships could be worth more than $1.2 billion.

    In another collaboration, Takeda and Skyhawk Therapeutics will use Skyhawk’s SkySTAR technology platform to discover and develop small molecule treatments for certain neurological disease targets.

    StrideBio and Takeda partnered to develop in vivo AAV-based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets that could be worth up to $700 million. These programs aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system.
    LegoChem Biosciences entered a research collaboration and license agreement with Takeda for the development of antibody-drug conjugates (ADCs) in immuno-oncology that could be worth up to roughly $410 million.

    HemoShear Therapeutics extended its partnership with Takeda to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH) in a deal worth $470 million if milestones are met.

    Takeda Dunboyne Biologics entered into a collaboration with Applied Process Company (APC) in Dublin, Ireland to design, optimize and deliver scale-independent process improvements for Takeda’s portfolio of biologics-based medicines for rare diseases. The companies completed their first partnership program in June, which used advanced computational, fluid-dynamic models to better understand and characterize the process equipment at Takeda’s biologics facility in Dunboyne, Co. Meath. Takeda took official ownership of the new facility in June. This ‘paperless’ facility is designed with single-use technology to manufacture antibody and enzyme-based therapies for rare diseases. 

    Lastly, Takeda unveiled plans to open a new plant in Singen, Germany that will manufacture the company's dengue vaccine candidate, TAK-003. Phase III results show the vaccine is effective against the mosquito-borne virus. The company began construction in 2016 and invested approximately $140 million to build the facility. 

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20


    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 04 Johnson & Johnson

      04 Johnson & Johnson

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login